Pfizer ends research for new Alzheimer''s, Parkinson's drugs
Pfizer is not making any changes to research and development funding for tanezumab, which is marketed as a treatment for joint pain from osteoarthritis, fibromyalgia treatment Lyrica, or its rare disease program.
Pfizer Inc is abandoning research to find new drugs aimed at treating Alzheimer`s and Parkinson`s disease. Image source: Reuters